Cost–effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore

References

• 1 Rho YH, Zhu Y, Choi HK. The epidemiology of uric acid and fructose. Semin. Nephrol. 31(5), 410–419 (2011).
  Medline CASGoogle Scholar
• 2 Khanna D, Fitzgerald JD, Khanna PP et al. 2012 American college of rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 64(10), 1431–1446 (2012).
  CASGoogle Scholar
• 3 Zhang W, Doherty M, Bardin T et al. Eular evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann. Rheum. Dis. 65(10), 1312–1324 (2006).
  Medline CASGoogle Scholar
• 4 Lin MS, Dai YS, Pwu RF, Chen YH, Chang NC. Risk estimates for drugs suspected of being associated with Stevens–Johnson syndrome and toxic epidermal necrolysis: a case-control study. Intern. Med. J. 35(3), 188–190 (2005).
  MedlineGoogle Scholar
• 5 Halevy S, Ghislain PD, Mockenhaupt M et al. Allopurinol is the most common cause of Stevens–Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J. Am. Acad. Dermatol. 58(1), 25–32 (2008).
  MedlineGoogle Scholar
• 6 Roujeau J-C, Kelly JP, Naldi L et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N. Engl. J. Med. 333(24), 1600–1608 (1995).
  Medline CASGoogle Scholar
• 7 Mockenhaupt M, Viboud C, Dunant A et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EUROSCAR study. J. Invest. Dermatol. 128(1), 35–44 (2008).
  Medline CASGoogle Scholar
• 8 Singapore Health Sciences Authority. Serious skin reactions associated with allopurinol. Adverse Drug Reactions News (2009). www.hsa.gov.sg/content/hsa/en/Health_Products_Regulation/Safety_Information_and_Product_Recalls/Product_Safety_Alerts/2009/serious_skin_reactions.html
  Google Scholar
• 9 Mahar PD, Wasiak J, Hii B et al. A systematic review of the management and outcome of toxic epidermal necrolysis treated in burns centres. Burns 40(7), 1245–1254 (2014).
  MedlineGoogle Scholar
• 10 Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N. Engl. J. Med. 331(19), 1272–1285 (1994).
  Medline CASGoogle Scholar
• 11 Kaniwa N, Saito Y, Aihara M et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 9(11), 1617–1622 (2008).
  CASGoogle Scholar
• 12 Tassaneeyakul W, Jantararoungtong T, Chen P et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet. Genomics 19(9), 704–709 (2009).
  Medline CASGoogle Scholar
• 13 Somkrua R, Eickman EE, Saokaew S, Lohitnavy M, Chaiyakunapruk N. Association of HLA-B*5801 allele and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med. Genet. 12, 118 (2011).
  Medline CASGoogle Scholar
• 14 Jung JW, Song WJ, Kim YS et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol. Dial. Transplant. 26(11), 3567–3572 (2011).
  Medline CASGoogle Scholar
• 15 Hung S-I, Chung W-H, Liou L-B et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102(11), 4134–4139 (2005).
  Medline CASGoogle Scholar
• 16 Zineh I, Mummaneni P, Lyndly J et al. Allopurinol pharmacogenetics: assessment of potential clinical usefulness. Pharmacogenomics 12(12), 1741–1749 (2011).
  CASGoogle Scholar
• 17 Hershfield MS, Callaghan JT, Tassaneeyakul W et al. Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-b genotype and allopurinol dosing. Clin. Pharmacol. Ther. 93(2), 153–158 (2013).
  Medline CASGoogle Scholar
• 18 European Medicine Agency CFMPFHU, Pharmacovigilance Working Party. Allopurinol: risk of skin reactions associated with HLA-B*5801 allele. Pharmacovigilance Working Party (PhVWP) monthly report on safety concerns, guidelines and general matters. EMA/CHMP/PhVWP/438980/2012. www.ema.europa.eu/docs/en_GB/document_library/Report/2012/07/WC500130391.pdf
  Google Scholar
• 19 Taiwan Food and Drug Administration. Drug Safety News (2009). www.fda.gov.tw/tc/siteListContent.aspx?sid=1571&id=7616&chk=1197ef3b-eda3-4a7b-95e0-7c6e7013d32e¶m=pn%3D69%26sid%3D1571#.VGtc8vmUd9g
  Google Scholar
• 20 dbMHC database. www.ncbi.nlm.nih.gov/projects/gv/mhc/ihwg.cgi
  Google Scholar
• 21 Garcia-Doval I, Lecleach L, Bocquet H, Otero X, Roujeau J. Toxic epidermal necrolysis and Stevens–Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch. Dermatol. 136(3), 323–327 (2000).
  Medline CASGoogle Scholar
• 22 Firestein GS, Kelley W, Ruddy S, Harris E, Sledge C. Textbook of Rheumatology. WB Saunders, PA, USA (1997).
  Google Scholar
• 23 Singapore Department of Statistics. Life expectancy at birth. www.singstat.gov.sg/statistics/visualising_data/chart/Life_Expectancy_At_Birth.html
  Google Scholar
• 24 Jordan KM, Cameron JS, Snaith M et al. British Society for rheumatology and British health professionals in rheumatology guideline for the management of gout. Rheumatology 46(8), 1372–1374 (2007).
  MedlineGoogle Scholar
• 25 Sarawate CA, Brewer KK, Yang W et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin. Proc. 81(7), 925–934 (2006).
  MedlineGoogle Scholar
• 26 Reinders MK, Haagsma C, Jansen TL et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann. Rheum. Dis. 68(6), 892–897 (2009).
  Medline CASGoogle Scholar
• 27 Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat. Rev. Rheumatol. 6(1), 30–38 (2010).
  Medline CASGoogle Scholar
• 28 Reinders MK, Van Roon EN, Jansen TL et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann. Rheum. Dis. 68(1), 51–56 (2009).
  Medline CASGoogle Scholar
• 29 Ramasamy SN, Korb-Wells CS, Kannangara DR et al. Allopurinol hypersensitivity: a systematic review of all published cases, 1950–2012. Drug Saf. 36(10), 953–980 (2013).
  Medline CASGoogle Scholar
• 30 Yap F, Wahiduzzaman M Pubalan M. Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in Sarawak: a four years’ review. Egypt. Dermatol. Online J. 4, 1–13 (2008).
  Google Scholar
• 31 Oplatek A, Brown K, Sen S, Halerz M, Supple K, Gamelli RL. Long-term follow-up of patients treated for toxic epidermal necrolysis. J. Burn Care Res. 27(1), 26–33 (2006).
  MedlineGoogle Scholar
• 32 Yip L, Thong B, Lim J et al. Ocular manifestations and complications of Stevens–Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy 62(5), 527–531 (2007).
  Medline CASGoogle Scholar
• 33 Gueudry J, Roujeau JC, Binaghi M, Soubrane G, Muraine M. Risk factors for the development of ocular complications of Stevens–Johnson syndrome and toxic epidermal necrolysis. Arch. Dermatol. 145(2), 157–162 (2009).
  MedlineGoogle Scholar
• 34 Dong D, Sung C, Finkelstein EA. cost–effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology 79(12), 1259–1267 (2012).
  MedlineGoogle Scholar
• 35 Waduthantri S, Yong SS, Tan CH et al. Cost of dry eye treatment in an Asian clinic setting. PLoS ONE 7(6), e37711 (2012).
  Medline CASGoogle Scholar
• 36 Beard S, Scheele B, Nuki G, Pearson I. cost–effectiveness of febuxostat in chronic gout. Eur. J. Health Econ. 15(5), 453–463 (2013).
  MedlineGoogle Scholar
• 37 Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W. Utility assessment among patients with dry eye disease. Ophthalmology 110(7), 1412–1419 (2003).
  MedlineGoogle Scholar
• 38 Schumacher HR Jr., Becker MA, Wortmann RL et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 59(11), 1540–1548 (2008).
  Medline CASGoogle Scholar
• 39 Becker MA, Schumacher Jr HR, Wortmann RL et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. 353(23), 2450–2461 (2005).
  Medline CASGoogle Scholar
• 40 Pui K, Gow PJ, Dalbeth N. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. J. Rheumatol. 40(6), 872–876 (2013).
  Medline CASGoogle Scholar
• 41 Pillai NE, Okada Y, Saw W-Y et al. Predicting HLA alleles from high-resolution SNP data in three southeast Asian populations. Hum. Mol. Genet. 23(16), 4443–4451 (2014).
  Medline CASGoogle Scholar
• 42 Singapore Pharmacogenomics Portal. www.statgen.nus.edu.sg/˜SPGx/SPGx_Main.php
  Google Scholar
• 43 Thong BY. Stevens–Johnson syndrome/toxic epidermal necrolysis: an Asia-Pacific perspective. Asia Pac. Allergy 3(4), 215–223 (2013).
  MedlineGoogle Scholar
• 44 Robinson PC, Merriman TR, Herbison P, Highton J. Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999–2009. Rheumatology 52(1), 118–126 (2013).
  MedlineGoogle Scholar
• 45 Monetary Authority of Singapore. Foreign exchange rates. https://secure.mas.gov.sg/msb/ExchangeRates.aspx
  Google Scholar
• 46 Grosse SD. Assessing cost–effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Revi. Pharmacoecon. Outcomes Res. 8(2), 165–178 (2008).
  MedlineGoogle Scholar
• 47 How NICE measures value for money in relation to public health interventions. http://publications.nice.org.uk/how-nice-measures-value-for-money-in-relation-to-public-health-interventions-lgb10b/nices-approach-to-economic-analysis-for-public-health-interventions
  Google Scholar
• 48 US Food Drug Administration. Uloric Safety Labeling Changes Approved by FDA Centre for Drug Evaluation and Research (CDER). www.fda.gov/safety/medwatch/safetyinformation/ucm243770.htm
  Google Scholar
• 49 Park DJ, Kang JH, Lee JW et al. cost–effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea. Arthritis Care Res. (Hoboken) 67(2), 280–287 (2015).
  MedlineGoogle Scholar
• 50 Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum. 29(1), 82–87 (1986).
  Medline CASGoogle Scholar
• 51 Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann. Rheum. Dis. 74(4), 661–667 (2014).
  MedlineGoogle Scholar
• 52 Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann. Rheum. Dis. 66(10), 1311–1315 (2007).
  Medline CASGoogle Scholar
• 53 Doherty M, Jansen TL, Nuki G et al. Gout: why is this curable disease so seldom cured? Ann. Rheum. Dis. 71(11), 1765–1770 (2012).
  MedlineGoogle Scholar
• 54 Lee HY, Ariyasinghe JT, Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? Singapore Med. J. 49(5), 384–387 (2008).
  Medline CASGoogle Scholar
• 55 Yang CY, Chen CH, Deng ST et al. Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan. JAMA Intern. Med. 175(9), 1550–1557 (2015).
  MedlineGoogle Scholar